ClinicalTrials.gg

Program

GB268

A development code.

Its studies are mostly in Breast Neoplasms, led by 2 companies.

Furthest: phase 2, since Mar 16, 20252 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Edding Genor Group11 open or runningphase 1since Mar 16, 2025Mar 16, 2025Mar 2027phase 1 · NCT06934616
Eddingpharm (Zhuhai)11 open or runningphase 2since Jul 23, 2026Jul 23, 2026Aug 1, 2029phase 2 · NCT07738341

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2025First study: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12New to Edding Genor GroupEdding Genor Group · NCT06934616 · 330 planned
  2. Jul 23, 2026Eddingpharm (Zhuhai)'s first study: phase 2 study in Breast NeoplasmsNew to Eddingpharm (Zhuhai)Eddingpharm (Zhuhai) · NCT07738341 · 270 planned

Ahead

  1. Mar 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12Edding Genor Group · NCT06934616
  2. Aug 1, 2029Primary completion: phase 2 study in Breast NeoplasmsEddingpharm (Zhuhai) · NCT07738341

TargetBeta

CTLA4 →read by rule
“GB268 is a tri-specific antibody targeting PD-1, CTLA-4, and VEGF.”study text, by rule · the study

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
tremelimumabruleAstraZenecaphase 347
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
gotistobartruleoncoc4-incphase 35
zalifrelimabruleAgenusphase 26
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07738341Breast Neoplasms2Not yet recruitingEddingpharm (Zhuhai)Aug 1, 2029270
NCT06934616Diabetes Mellitus, Insulin-Dependent, 121Not yet recruitingEdding Genor GroupMar 2027330

How it is read

Names in the registry

  • “GB268”, 2 entries

Codes read as this program: GB268.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.